Literature DB >> 6839023

Demonstration of a natural antigalactosyl IgG antibody on thalassemic red blood cells.

U Galili, A Korkesh, I Kahane, E A Rachmilewitz.   

Abstract

A modified antiglobulin test, based on the high affinity between the Fc portion of the red blood cell (RBC) bound IgG and the Fc receptor on the myeloid cell K-562, was utilized for demonstration of immunoglobulins (Ig) on thalassemic RBC. Ig was found on the RBC of 73 out of 80 patients with thalassemia. The immunoglobulins on the thalassemic RBC belonged to the IgG subclass and were autoreactive. Elution studies utilizing various carbohydrates, or by thermal stripping, indicated that at least part of the IgG molecules found on the thalassemic RBC were specifically reactive with terminal galactosyl residues on the RBC membrane. IgG antibodies with similar reactivity were also demonstrated in normal human serum. These natural antigalactosyl IgG antibodies from normal sera could bind to IgG-depleted thalassemic RBC. Thalassemic RBC and normal senescent RBC were previously found to contain reduced amounts of membrane sialic acid (SA). It is suggested that the antigalactosyl IgG antibodies interact with newly exposed galactosyl residues underlying the sialic acid units. Such interaction may lead to the shortened lifespan of thalassemic RBC and may result in sequestration of senescent normal RBC by the reticuloendothelial system.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6839023

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

Review 1.  Use of mouse models to study the mechanisms and consequences of RBC clearance.

Authors:  E A Hod; S A Arinsburg; R O Francis; J E Hendrickson; J C Zimring; S L Spitalnik
Journal:  Vox Sang       Date:  2010-03-21       Impact factor: 2.144

2.  A monoclonal antibody for terminal beta-galactose. Use in analysis of glycosphingolipids.

Authors:  A Kalisiak; E Oosterwijk; J G Minniti; L J Old; D A Scheinberg
Journal:  Glycoconj J       Date:  1991-02       Impact factor: 2.916

3.  Adhesion and erythrophagocytosis of human senescent erythrocytes by autologous monocytes and their inhibition by beta-galactosyl derivatives.

Authors:  J Vaysse; L Gattegno; D Bladier; D Aminoff
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

4.  Heinz bodies induce clustering of band 3, glycophorin, and ankyrin in sickle cell erythrocytes.

Authors:  S M Waugh; B M Willardson; R Kannan; R J Labotka; P S Low
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

5.  Excessive binding of natural anti-alpha-galactosyl immunoglobin G to sickle erythrocytes may contribute to extravascular cell destruction.

Authors:  U Galili; M R Clark; S B Shohet
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

6.  Band 3 and glycophorin are progressively aggregated in density-fractionated sickle and normal red blood cells. Evidence from rotational and lateral mobility studies.

Authors:  J D Corbett; D E Golan
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

Review 7.  Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody.

Authors:  U Galili
Journal:  Springer Semin Immunopathol       Date:  1993

8.  Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora.

Authors:  U Galili; R E Mandrell; R M Hamadeh; S B Shohet; J M Griffiss
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

9.  Oxidation as a possible mechanism of cellular aging: vitamin E deficiency causes premature aging and IgG binding to erythrocytes.

Authors:  M M Kay; G J Bosman; S S Shapiro; A Bendich; P S Bassel
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

10.  Differing erythrocyte membrane skeletal protein defects in alpha and beta thalassemia.

Authors:  E Shinar; E A Rachmilewitz; S E Lux
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.